Combination therapy does not improve ability to quit smoking after one year

Among cigarette smokers, the combined use of the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in better rates of smoking abstinence at 12 weeks, but rates were similar after one year, according to a study in the January 8 issue of JAMA.

Smoking accounts for 62 percent of deaths among female smokers and 60 percent of deaths among male smokers. Innovative pharmacotherapeutic approaches to tobacco-dependence treatment need investigation to reduce smoking-related death and disability, according to background information in the article. "Exploration of combination therapy with existing drugs may provide the best opportunity to advance treatment in the absence of any new pharmacotherapies for tobacco dependence."

Jon O. Ebbert, M.D., M.Sc., of the Mayo Clinic, Rochester, Minn., and colleagues investigated the efficacy of combination pharmacotherapy with and bupropion SR (sustained-release) for smoking cessation, compared with varenicline alone (monotherapy). The trial included 315 adults who completed the study. Participants were randomized to 12 weeks of varenicline and bupropion SR or varenicline and placebo. There was follow-up through week 52.

The primary outcome was abstinence rates at week 12, defined as prolonged abstinence (no smoking from 2 weeks after the target quit date) and 7-day point-prevalence abstinence (no smoking past 7 days). Outcomes were biochemically confirmed.

Combination therapy was associated with significantly higher prolonged smoking abstinence rates at 12 (53.0 percent vs. 43.2 percent) and 26 weeks (36.6 percent vs. 27.6 percent) compared with varenicline alone. No significant differences were observed in prolonged smoking abstinence rates between the 2 groups at 52 weeks (30.9 percent vs. 24.5 percent).

No significant differences were observed between the 2 groups at any time point for 7-day point-prevalence smoking abstinence rates.

Anxiety was reported more commonly with than with varenicline monotherapy (7.2 percent vs. 3.1 percent), as were depressive symptoms (3.6 percent vs. 0.8 percent).

"Among , combined use of varenicline and bupropion, compared with varenicline alone, resulted in an increase in prolonged abstinence but not 7-day point-prevalence at 12 and 26 weeks; neither outcome was significantly different at 52 weeks. Further research is required to determine the role of combination treatment in ," the authors conclude.

More information: DOI: 10.1001/jama.2013.283185

add to favorites email to friend print save as pdf

Related Stories

Varenicline helps smokers with depression to quit smoking

Sep 16, 2013

About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder (MDD) have greater difficulty quitting.

Quitting smoking: Licensed medications are effective

May 30, 2013

Nicotine replacement therapy and other licensed drugs can help people quit smoking, according to a new systematic review published in The Cochrane Library. The study, which is an overview of previous Cochrane reviews, suppor ...

Recommended for you

Electronic health records tied to shorter time in ER

23 hours ago

(HealthDay)—Length of emergency room stay for trauma patients is shorter with the use of electronic health records, according to a study published in the September issue of the Journal of Emergency Nursing.

CDC: Almost everyone needs a flu shot

Sep 19, 2014

(HealthDay)—Less than half of all Americans got a flu shot last year, so U.S. health officials on Thursday urged that everyone 6 months and older get vaccinated for the coming flu season. "It's really unfortunate ...

User comments